CSRxP: BIG PHARMA’S EGREGIOUS GLP-1 PRICES AND ANTI-COMPETITIVE TACTICS UNSUSTAINABLE FOR PATIENTS AND U.S. HEALTH CARE SYSTEM
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
Brand Name Drug Companies Applying Price-Hiking, Patent Abuse Playbook to… Read More
Lawmakers Should Focus on Holding Big Pharma Accountable for Egregious Pricing… Read More
Letter Encourages Lawmakers to Advance Bipartisan Solutions to Hold Big Pharma… Read More
Campaign Will Add Support to Growing Bipartisan Momentum to Crack Down on Big… Read More
New Report Emphasizes The “Pharmaceutical Industry’s Patent Gamesmanship… Read More
Lowering Prices for Some Patients at Some Dosages Will Have Limited Impact,… Read More
Price Hikes and Egregious Prices on Blockbuster Drugs Boost Profits… Read More
Analysis Finds GLP-1 Blockbusters and “Multimillion-Dollar Gene Therapies”… Read More
Big Pharma Continues Raking in Expectation-Beating Profits and Revenue Fueled… Read More
Bipartisan, Market-Based Solution Would Help Crack Down on Anti-Competitive… Read More
More Brand Name Drug Makers Beat Wall Street Earnings After Hiking Prices This… Read More